Table 4 Impact of the absolute lymphocyte count on survival in 721 MDS patients without hematopoietic stem cell transplantation or induction chemotherapy according to MDS subtypes

From: Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients

 

Median OS [months]

Median OS [months]

 

n

ALC < 1.2 × 109/l

95% CI

ALC ≥ 1.2 × 109/l

95% CI

p log rank

Whole cohort

721

36

29–43

56

48–64

0.001

Subgroups according to WHO2016

MDS-SLD

57

not reached

n.a

141

26–256

0.271

MDS-MLD

227

40

26–54

44

30–58

0.433

MDS-RS-SLD

42

62

2–122

155

29–281

<0.001

MDS-RS-MLD

66

47

19–75

70

44–96

0.310

MDS del(5q)

102

62

48–76

77

47–107

0.174

MDS-EB-1

108

19

6–32

25

19–31

0.291

MDS-EB-2

109

11

6–16

22

14–30

0.268

MDS-U

10

95

n.a.

63

n.a.

0.757

Risk categories according to IPSS-R

IPSS-R very low

51

101

42–160

104

71–137

0.731

IPSS-R low

265

56

46–66

106

70–142

0.002

IPSS-R intermediate

187

50

33–67

41

31–51

0.639

IPSS-R high

121

29

19–39

24

19–29

0.538

IPSS-R very high

97

8

6–10

13

9–17

0.127

Back to article page